Avacta Group PLC Hardman Research: Great strides to strategic goals
October 17 2016 - 8:00AM
RNS Non-Regulatory
TIDMAVCT
Avacta Group PLC
17 October 2016
Hardman Research: Great strides towards strategic goals
Great strides towards strategic goals: Avacta is the proprietary
owner of Affimer technology for the development of
bio-therapeutics, diagnostic tests and research reagents. Affimers
represent a revolutionary alternative to the established antibody
technology which dominates the drug industry despite its
limitations. Avacta has made considerable progress towards its
strategic goal to have a first-in-man Affimer therapeutic by the
end of 2019. Meanwhile, its reagent business is continuing to
deliver on three initial areas of strategic focus. There will be
greater recognition of the long-term potential of Affimers in the
enterprise value as Avacta signs more licensing/collaboration
deals.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/avacta-documents/17.10.16-great-strides-towards-strategic-goals.pdf
To contact us: Contact: Dr Martin Hall
Hardman & Co mh@hardmanandco.com
11/12 Tokenhouse Dr Dorothea Hill
Yard dmh@hardmanandco.com
London Dr Gregoire Pave
EC2R 7AS gp@hardmanabdco.com
Telephone: +44 20 7929 3399
Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABBBDGDUBBGLR
(END) Dow Jones Newswires
October 17, 2016 08:00 ET (12:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024